Isomorphic Labs Completes $500 Million Series C Funding
Isomorphic Labs, the AI drug discovery company founded by Demis Hassabis, has completed a $500 million Series C funding round. Investors include Greenoaks, Sequoia Capital and Andreessen Horowitz, with Alphabet continuing to participate. The company focuses on using AI to design and develop new drugs. Demis Hassabis said this will accelerate its mission to tackle diseases and reduce the time and cost required to discover new medicines.
Why read this
AI score 72
Isomorphic Labs has completed a $500 million Series C funding round, giving readers insight into the current scale of funding and the main investors in the AI pharmaceutical sector.
Topics
View original postThrilled to announce $5B in funding for @IsomorphicLabs to accelerate our mission to Solve All Disease. We continue to make rapid progress reimagining drug design from first principles with AI to radically cut the time & cost to find new medicines. Gradually, then all at once... https://t.co/ihOS3L9vPC
View original
Thrilled to announce $5B in funding for @IsomorphicLabs to accelerate our mission to Solve All Disease. We continue to make rapid progress reimagining drug design from first principles with AI to radically cut the time & cost to find new medicines. Gradually, then all at once... https://t.co/ihOS3L9vPC
Body
Isomorphic Labs raised $5 Billion in Series C funding from Greenoaks, Sequoia Capital and Andreessen Horowitz, with continued investment from Alphabet.
> Isomorphic Labs, founded by Demis Hassabis, is focussed on designing and developing new medicines with AI, ushering in a new era of biomedical breakthroughs.
Drug development is a huge area that everyone is expecting to get pushed forward by AI.
Soon? 👀
AI Trends